Rossari Biotech reports 38% PAT growth in Q2FY24

Rossari Biotech Limited, a specialty-chemicals manufacturer has announced its financial results for the quarter ended September 30, 2023.

 

Consolidated Q2 FY24 performance overview

 

  • Revenue from operations stood at ₹483.5cr as against ₹425.4cr 
  • EBITDA at ₹63.6cr as against ₹56.5cr 
  • EBITDA margin at 13.2% as against 13.3% 
  • PAT stood at ₹32.9cr as against ₹23.9cr 
  • EPS (Diluted) stood at ₹6.0 as against ₹4.3

 

Consolidated H1 FY24 performance overview

 

  • Revenue from operations stood at ₹894.1cr as against ₹860.1cr 
  • EBITDA at Rs 121.3 crore as against ₹114.3cr 
  • EBITDA margin at 13.6% as against 13.3% 
  • PAT stood at ₹62.2cr as against ₹52.6cr 
  • EPS (Diluted) stood at ₹11.2 as against ₹9.5

 

Commenting on the Q2 FY2024 performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said "We are pleased to report a record quarter for Rossari, with the best ever performance both in terms of Revenue and Profits. The flag bearers for this strong performance were our core HPPC and TSC division. 

 

While HPPC grew by 21%, TSC was up 5% in revenue as compared to the corresponding quarter in the previous year. In the AHN division, we witnessed subdued performance due to seasonal softness in demand. 

 

Overall, the results for this quarter underscore the resilience and adaptability of our business model. We believe that our strategic emphasis on customer diversification, improving our capacity utilization and continuous R&D initiatives, positions us favourably to ensure sustainable operational and financial performance in the future.”

 

At around 9:35 AM, shares of Rossari Biotech were trading in the green by 0.04% at Rs 821.90 per share on the BSE.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

14 mins read . 06 Dec 2024

Stocks Under 1000 Rupees in India

  • 0 people read
blog-logo

Economy

blog-logo

8 mins read . 05 Dec 2024

History of Reliance Group

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions